Liquid biopsy in H3K27M diffuse midline glioma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Pediatric Oncology

Background:

• Diffuse midline glioma (DMG) with H3K27M mutation is a challenging pediatric brain tumor with poor prognosis.
• Traditional biopsy and MRI monitoring pose risks and limitations for DMG diagnosis and treatment assessment.
• There is a critical need for minimally invasive biomarkers for H3K27M DMG detection and monitoring.

Purpose of the Study:

• To review current liquid biopsy modalities for detecting H3K27M biomarkers in DMG.
• To compare the effectiveness of different liquid biopsy approaches in diagnosis and treatment monitoring.
• To discuss future directions in H3K27M DMG therapeutic monitoring.

Main Methods:

• Review of existing literature on liquid biopsy techniques for H3K27M detection.
• Analysis of biomarker detection in cerebrospinal fluid (CSF), blood, and urine.
• Examination of cell-free DNA (cfDNA) monitoring in CSF and plasma during ONC201 therapy.

Main Results:

• Liquid biopsy modalities show promise for detecting H3K27M biomarkers.
• cfDNA monitoring in CSF and plasma is being explored for treatment response assessment.
• Emerging biomarkers include mitochondrial DNA, mutant histones, and novel sequencing approaches.

Conclusions:

• Liquid biopsy represents a significant advancement for H3K27M DMG management.
• Further research into novel biomarkers and sequencing methods will enhance diagnostic and monitoring capabilities.
• Minimally invasive monitoring is crucial for improving outcomes in pediatric H3K27M DMG.